Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 3/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18095998 | 0.80 | P2RX7 (0.48) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL31387285 | 0.79 | MAPK1 (0.46) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL30708588 | 0.78 | P2RX7 (0.43) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL31570487 | 0.78 | P2RX7 (0.47) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL30965862 | 0.75 | P2RX7 (0.47) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL21585195 | 0.74 | P2RX7 (0.40) | MAPK1P2RX7 | |
| SCHEMBL19326734 | 0.72 | P2RX7 (0.38) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL31387215 | 0.72 | MAPK1 (0.46) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL2753979 | 0.71 | P2RX7 (0.43) | MAPK1P2RX7LPLLIPG | |
| SCHEMBL3655929 | 0.71 | P2RX7 (0.47) | MAPK1P2RX7LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101944-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-05-15 | — | — | WO | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | MAPK1 1424/4885P2RX7 196/4885LPL 2234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.